Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: A preliminary report

Abstract
Summary Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1+ARA-C on days 1–5; R 2 = courses of daunorubicin on days 1 and 2+ARA-C on days 4–8; R 3 = courses of daunorubicin-DNA complex on days 1–2+ ARA-C on days 4–8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.